Fusion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	62.77	45.33	54.79	92.41	67.12	29.08
Short-Term Investments	172.15	127.01	147.9	131.88	0	0
Cash & Cash Equivalents	234.93	172.35	202.69	224.29	67.12	29.08
Cash Growth	36.31%	-14.97%	-9.63%	234.16%	130.81%	-
Receivables	0.01	0.06	0.36	0	0	0
Other Current Assets	8.46	6.59	8.72	3.87	-0.57	1.16
Total Current Assets	243.4	179	211.76	228.16	66.55	30.24
Property, Plant & Equipment	23.9	10.32	9.45	1.97	1.27	1.1
Long-Term Investments	13.74	15.76	19.99	77.08	0	0
Other Long-Term Assets	4.81	13.99	11.07	3.46	1.58	0.05
Total Long-Term Assets	42.44	40.07	40.51	82.51	2.85	1.16
Total Assets	285.84	219.06	252.27	310.68	69.4	31.39
Accounts Payable	1.86	2.69	2.2	3.4	0.83	0.35
Deferred Revenue	1	3	4.04	5	0	0
Current Debt	4.16	1.44	1.22	0	0	0
Other Current Liabilities	9.2	7.94	5.06	3.46	3.44	1.25
Total Current Liabilities	16.22	15.07	12.51	11.86	4.27	1.6
Long-Term Debt	46.17	38.81	5.51	0	0	0
Other Long-Term Liabilities	0.97	2.97	2.8	4.31	6.06	0.17
Total Long-Term Liabilities	47.14	41.78	8.3	4.31	6.06	0.17
Total Liabilities	63.36	56.84	20.82	16.16	10.34	1.77
Total Debt	50.33	40.25	6.72	0	0	0
Debt Growth	25.04%	498.82%	-	-	-	-
Retained Earnings	-376.76	-281.86	-194.25	-113.2	-34.77	-18.59
Comprehensive Income	0.24	-0.47	-0.12	0.04	0	0
Shareholders' Equity	222.48	162.22	231.46	294.51	-33.49	-17.92
Net Cash / Debt	184.6	132.09	195.96	224.29	67.12	29.08
Net Cash / Debt Growth	39.75%	-32.59%	-12.63%	234.16%	130.81%	-
Net Cash Per Share	2.81	3.02	4.60	10.18	35.04	15.53
Working Capital	227.18	163.93	199.25	216.31	62.28	28.64
Book Value Per Share	3.39	3.71	5.43	13.37	-17.48	-9.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).